Richard Bucala

Dr. Richard Bucala

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2003 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LLLin Leng
Lin Leng
CMChristine Noel Metz
Christine Noel Metz
YFYan Fang
Yan Fang
JXJing Xu
Jing Xu
SDSeamas C. Donnelly
Seamas C. Donnelly
RBRichard Bucala
Richard Bucala
Macrophage migration inhibitory factor (MIF) accounts for one of the first cytokine activities to have been described, and it has emerged recently to be an important regulator of innate and adaptive immunity. MIF is an upstream activator of monocytes/macrophages, and it is centrally involved in the pathogenesis of septic shock, arthritis, and other inflammatory conditions. The protein is encoded by a unique but highly conserved gene, and X-ray crystallography studies have shown MIF to define a new protein fold and structural superfamily. Although recent work has begun to illuminate the signal transduction pathways activated by MIF, the nature of its membrane receptor has not been known. Using expression cloning and functional analysis, we report herein that CD74, a Type II transmembrane protein, is a high-affinity binding protein for MIF. MIF binds to the extracellular domain of CD74, and CD74 is required for MIF-induced activation of the extracellular signal–regulated kinase–1/2 MAP kinase cascade, cell proliferation, and PGE2 production. A recombinant, soluble form of CD74 binds MIF with a dissociation constant of ∼9 × 10−9 Kd, as defined by surface plasmon resonance (BIAcore analysis), and soluble CD74 inhibits MIF-mediated extracellular signal–regulated kinase activation in defined cell systems. These data provide a molecular basis for MIF's interaction with target cells and identify it as a natural ligand for CD74, which has been implicated previously in signaling and accessory functions for immune cell activation.

1 October 2006 in Immunity
Verified
Journal Article
Closed access
XSXuerong Shi
Xuerong Shi
LLLin Leng
Lin Leng
TWTian Wang
Tian Wang
WWWenkui Wang
Wenkui Wang
XDXin Du
Xin Du
RBRichard Bucala
Richard Bucala

13 June 2019 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
IKInsoo Kang
Insoo Kang
RBRichard Bucala
Richard Bucala

4 August 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MMMelanie Merk
Melanie Merk
SZSwen Zierow
Swen Zierow
LLLin Leng
Lin Leng
RDRituparna Das
Rituparna Das
XDXin Du
Xin Du
RBRichard Bucala
Richard Bucala
Macrophage migration inhibitory factor (MIF) is a pivotal regulator of the immune response. Neutralization or genetic deletion of MIF does not completely abrogate activation responses, however, and deletion of the MIF receptor, CD74, produces a more pronounced phenotype than MIF deficiency. We hypothesized that these observations may be explained by a second MIF-like ligand, and we considered a probable candidate to be the protein encoded by the homologous, D -dopachrome tautomerase (D-DT) gene. We show that recombinant D-DT protein binds CD74 with high affinity, leading to activation of ERK1/2 MAP kinase and downstream proinflammatory pathways. Circulating D-DT levels correlate with disease severity in sepsis or malignancy, and the specific immunoneutralization of D-DT protects mice from lethal endotoxemia by reducing the expression of downstream effector cytokines. These data indicate that D-DT is a MIF-like cytokine with an overlapping spectrum of activities that are important for our understanding of MIF-dependent physiology and pathology.

1 April 2006 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
TQTimothy E. Quan
Timothy E. Quan
SCShawn E. Cowper
Shawn E. Cowper
RBRichard Bucala
Richard Bucala

26 September 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YMY. Mizue
Y. Mizue
SGS. Ghani
S. Ghani
LLL. Leng
L. Leng
CMC. McDonald
C. McDonald
PKP. Kong
P. Kong
RBRichard Bucala
Richard Bucala
Macrophage migration inhibitory factor (MIF) is an immunologic regulator that is expressed in inflammatory and autoimmune disorders. We investigated MIF's role in asthma using genetic approaches in a mouse model and in a cohort of asthma patients. Mice genetically deficient in MIF that were primed and aerosol-challenged with ovalbumin showed less pulmonary inflammation and lower airway hyperresponsiveness than genetically matched, wild-type controls. MIF deficiency also resulted in lower titers of specific IgE, IgG 1 , and IgG 2a , and decreased pulmonary, T H 2 cytokine levels. IL-5 concentrations were lower and corresponded to decreased eosinophil numbers in bronchoalveolar lavage fluid. T cell studies also showed a lower level of antigen-specific responses in MIF-KO versus wild-type mice. In an analysis of 151 white patients with mild, moderate, or severe asthma (Global Initiative for Asthma criteria), a significant association was found between mild asthma and the low-expression, 5-CATT MIF allele. Pharmacologic inhibition of MIF may be beneficial and could be guided by the MIF genotype of affected individuals.